Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 16/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941205 | 0.79 | EPHX2 (0.66) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL8429525 | 0.77 | EPHX1 (0.64) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL1416140 | 0.77 | EPHX1 (0.64) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL966655 | 0.77 | EPHX1 (0.72) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL13480593 | 0.77 | EPHX1 (0.72) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL13480574 | 0.77 | EPHX1 (0.72) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL14654457 | 0.76 | EPHX1 (0.61) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL8432351 | 0.75 | EPHX1 (0.60) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL965080 | 0.75 | EPHX1 (0.69) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL12196028 | 0.74 | EPHX1 (1.00) | EPHX2EPHX1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9133183-B2 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | EPHX2 3659/4885EPHX1 2730/4885KDM4E 821/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | EPHX2 3659/4885EPHX1 2730/4885KDM4E 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.